- Home
- SCNI vs CHRO Comparison
SCNI vs CHRO Comparison
Compare SCNI & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- CHRO
- Stock Information
- Founded
- SCNI 2003
- CHRO 2002
- Country
- SCNI Israel
- CHRO United States
- Employees
- SCNI N/A
- CHRO N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- CHRO
- Sector
- SCNI Health Care
- CHRO
- Exchange
- SCNI Nasdaq
- CHRO Nasdaq
- Market Cap
- SCNI 3.5M
- CHRO 4.2M
- IPO Year
- SCNI N/A
- CHRO 2024
- Fundamental
- Price
- SCNI $3.48
- CHRO $0.60
- Analyst Decision
- SCNI
- CHRO Strong Buy
- Analyst Count
- SCNI 0
- CHRO 1
- Target Price
- SCNI N/A
- CHRO N/A
- AVG Volume (30 Days)
- SCNI 13.2K
- CHRO 121.3K
- Earning Date
- SCNI 11-22-2024
- CHRO 11-13-2024
- Dividend Yield
- SCNI N/A
- CHRO N/A
- EPS Growth
- SCNI N/A
- CHRO N/A
- EPS
- SCNI 8.20
- CHRO N/A
- Revenue
- SCNI $452,000.00
- CHRO N/A
- Revenue This Year
- SCNI N/A
- CHRO N/A
- Revenue Next Year
- SCNI N/A
- CHRO N/A
- P/E Ratio
- SCNI $0.42
- CHRO N/A
- Revenue Growth
- SCNI N/A
- CHRO N/A
- 52 Week Low
- SCNI $2.23
- CHRO $0.45
- 52 Week High
- SCNI $8.92
- CHRO $6.00
- Technical
- Relative Strength Index (RSI)
- SCNI 56.32
- CHRO 48.49
- Support Level
- SCNI $3.20
- CHRO $0.55
- Resistance Level
- SCNI $3.55
- CHRO $0.71
- Average True Range (ATR)
- SCNI 0.18
- CHRO 0.10
- MACD
- SCNI 0.03
- CHRO -0.00
- Stochastic Oscillator
- SCNI 51.72
- CHRO 23.98
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.